Abstract
In view of the results achieved by others with interferons and also with low doses of Cytosine-arabinoside, we have treated 24 patients with IFN alpha 2a and Hydroxyurea for induction, with addition of low dose Ara-C during IFN maintenance therapy when the cytogenetic results were deemed insufficient. Complete hematological responses were obtained in 75% of the cases. Cytogenetic responses were noted in 83% of 12 previously untreated (complete or almost complete response in 3) and in 50% of previously treated patients (complete or almost complete response in 3 patients).
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Child
-
Child, Preschool
-
Combined Modality Therapy
-
Cytarabine / administration & dosage
-
Drug Evaluation
-
Humans
-
Hydroxyurea / administration & dosage
-
Interferon Type I / therapeutic use*
-
Interferon alpha-2
-
Interferon-alpha / therapeutic use*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
-
Middle Aged
-
Recombinant Proteins
-
Remission Induction
Substances
-
Interferon Type I
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins
-
Cytarabine
-
Hydroxyurea